[Alpha interferon in condylomata acuminata and juvenile diabetes mellitus].
Persistent condylomata acuminata in a 21-year-old patient with diabetes mellitus were treated with highly purified interferon-alpha (IFN-alpha) obtained by recombinant DNA technology. Daily dose was 1.5 X 10(6) IU, given subcutaneously. Already during treatment the condylomata regressed. Two weeks after the end of therapy, i.e. after a total dose of 10.5 X 10(6) IU IFN-alpha, all condylomata had completely receded. Blood glucose levels remained constant with concomitant insulin therapy. Toxic side-effects or antibodies to IFN-alpha were not observed.
D000328:Adult; D001706:Biopsy; D003218:Condylomata Acuminata / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010412:Penile Neoplasms / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D010413:Penis / Q000382:microbiology / Q000473:pathology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins
Interferon-alpha bei Condylomata acuminata und juvenilem Diabetes mellitus.